

**THE PERRINE-DUPONT MEDICAL MONITORING
QUALIFIED SETTLEMENT FUND**

Financial Statements

December 31, 2025 and 2024

TABLE OF CONTENTS

	Page
INDEPENDENT ACCOUNTANT'S COMPILATION REPORT	3
FINANCIAL STATEMENTS	
Statements of Assets, Liabilities and Fund Balance - Modified Cash Basis	4
Statements of Revenue Collected, Claims and Expenses Paid and Changes in Fund Balance - Modified Cash Basis	5
Notes to Financial Statements	6

INDEPENDENT ACCOUNTANT'S COMPILATION REPORT

The Honorable Joseph F. Shaffer, Jr.
Circuit Judge of Harrison County

Edgar C. Gentle III, Esq.
Claims Administrator

Niall A. Paul, Esq.
Clifford F. Kinney, Jr., Esq.
DuPont Representatives on the Settlement Finance Committee

Virginia Buchanan, Esq.
Plaintiff Class Representative on the Settlement Finance Committee

Meredith McCarthy, Esq.
Guardian Ad Litem for Children

Management is responsible for the accompanying financial statements of The Perrine-Dupont Medical Monitoring Qualified Settlement Fund, which comprise the statement of assets, liabilities and fund balance - modified cash basis as of December 31, 2025, and the related statement of revenue collected, claims and expenses paid and changes in fund balance - modified cash basis for the year then ended, and the related notes to the financial statements in accordance with the modified cash basis of accounting. We have performed a compilation engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. We did not audit or review the financial statements nor were we required to perform any procedures to verify the accuracy or completeness of the information provided by management. We do not express an opinion, a conclusion, nor provide any assurance on these financial statements.

Emphasis of Matter

We were not engaged to and did not assess the ability of Dupont De Nemours and Company, et al. (Defendants) to meet their financial obligations to contribute to the Fund. Accordingly, we were unable to determine the adequacy of disclosures included in the notes to the accompanying financial statements – modified cash basis regarding risks and uncertainties involving the Defendants' ability to contribute to the Fund as required by the Court.

The 2024 financial statements were audited by other accountants, and they expressed a qualified opinion, which is described in the emphasis of matter paragraph above, on them in their report dated June 2, 2025.

BMSS, LLC

Birmingham, Alabama
July 8, 2026

THE PERRINE-DUPONT MEDICAL MONITORING QUALIFIED SETTLEMENT FUND
Statements of Assets, Liabilities and Fund Balance - Modified Cash Basis
December 31, 2025 and 2024

	<u>Compiled 2025</u>	<u>Audited 2024</u>
Assets		
Current assets		
Cash and cash equivalents	\$ 32,959	\$ 118,816
	<u>\$ 32,959</u>	<u>\$ 118,816</u>
Liabilities and Fund Balance		
Current liabilities		
Accounts payable	\$ 9,381	\$ 32,676
Fund balance	<u>23,578</u>	<u>86,140</u>
	<u>\$ 32,959</u>	<u>\$ 118,816</u>

See independent accountant's compilation report and notes to financial statements.

THE PERRINE-DUPONT MEDICAL MONITORING QUALIFIED SETTLEMENT FUND
Statements of Revenue Collected, Claims and Expenses Paid and Changes in
Fund Balance - Modified Cash Basis
Years ended December 31, 2025 and 2024

	Compiled 2025	Audited 2024
Revenue Collected		
Post implementation defendant funding	\$ 47,000	\$ -
Investment income	148	505
	<u>47,148</u>	<u>505</u>
Claims and Expenses Paid or Accrued		
Cash payments to medical providers on behalf of claimants	22,798	9,080
General and administrative expenses	27,774	14,013
Claims administrator fees	59,138	52,972
	<u>109,710</u>	<u>76,065</u>
Deficiency of revenue collected over claims and expenses paid or accrued and decrease in fund balance attributable to medical monitoring activities	(62,562)	(75,560)
Fund balance - beginning of year	<u>86,140</u>	<u>161,700</u>
Fund balance - end of year	<u><u>\$ 23,578</u></u>	<u><u>\$ 86,140</u></u>

See independent accountant's compilation report and notes to financial statements.

THE PERRINE-DUPONT MEDICAL MONITORING QUALIFIED SETTLEMENT FUND

Notes to Financial Statements

December 31, 2025 and 2024

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Fund

On December 23, 2010, the Honorable Thomas Bedell, Circuit Judge for the Circuit Court of Harrison County, West Virginia (Court), entered an Order Establishing Qualified Settlement Funds in Perrine, et al. v. E.I. DuPont Nemours and Company, et al. (DuPont or the Defendant), ordering the establishment of The Perrine-DuPont Medical Monitoring Qualified Settlement Fund (Fund) under Internal Revenue Code of 1986 as amended Section 468B. The Fund was formed to administer a class action settlement wherein it was alleged that the Defendants released heavy metals from the Spelter Smelter facility onto private real property in the class area and that these substances have health risks, with the Defendants strenuously denying those allegations. The Fund is overseen by the Claims Administrator who is paid claims administrator fees as reflected in the statements of revenue collected, claims and expenses paid, and changes in fund balance - modified cash basis.

Under the terms of the November 19, 2010 Memorandum of Understanding, which led to the settlement above, the Pre-Implementation Date Funding, which was received by the Fund on January 4, 2011 in the amount of \$4 million, is to be used for Fund fees and expenses incurred before Medical Monitoring was implemented (with implementation occurring on November 1, 2011) and to make cash payments to claimants. This contribution is called the Pre-Implementation Date Funding. DuPont is required to deposit additional monies annually, or as needed, into the Fund to cover the costs of the medical monitoring program, with DuPont making its first Post-Implementation Date Funding on October 31, 2011 in the amount of approximately \$2.8 million. No additional funding was required from 2012 to 2016, in 2018, in 2020, in 2022, or in 2024. Additional funding was received from DuPont in 2025, 2023, 2021, 2019, and 2017, in the amounts of \$47,000, \$200,000, \$65,000, \$275,000, and \$424,000, respectively, to cover the Fund's medical monitoring expenses. The Claims Administrator will seek additional funding as deemed necessary to cover the costs of the medical monitoring program.

By Order dated February 10, 2011, the Court approved an initial cash payment of \$200 to the Perrine Medical Monitoring Class Members who registered and had their membership in the Class verified (Verified Registrants) with the Court, subsequently increasing the Verified Registrant cash payment to \$400 by Order dated April 28, 2011. The final count of Verified Registrants is 5,890, with 4,169 Verified Registrants electing to participate in medical monitoring. After all Pre-Implementation Date expenses had been accrued, the Court, by Order dated June 28, 2012, authorized the Claims Administrator to issue a final Pre-Implementation Date funding dividend payment of \$55 to all Verified Registrants, representing the balance of the Pre-Implementation Date Funding, less a small administrative reserve. From inception through December 31, 2013, dividend payments to claimants totaled \$318,065. The \$25,743 of Pre-Implementation Date Funding was paid over into the Post-Implementation Date Funding on September 30, 2014.

THE PERRINE-DUPONT MEDICAL MONITORING QUALIFIED SETTLEMENT FUND

Notes to Financial Statements

December 31, 2025 and 2024

(Continued)

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Nature of Fund - Continued

The Post-Implementation Date Funding is used to pay for the settlement medical monitoring program, which, on November 1, 2011, began the first round of testing. There will be a total of 15 rounds of testing to be done every two years. During the first round of testing, approximately half of the claimants who signed up for medical monitoring were tested. The second, third, fourth and fifth rounds of testing began November 1, 2013, November 1, 2015, December 1, 2017, and November 1, 2019, respectively. COVID-19 delayed the start of the sixth round of testing from November 1, 2021 until June 1, 2022, and the seventh round of testing began November 1, 2024.

Per Court Order dated December 29, 2017, the Perrine-DuPont Property Remediation Qualified Settlement Fund was terminated as of February 28, 2018, as the Remediation Program was completed in June 2016. The remaining funds of approximately \$304,000 were transferred to a remediation fund sinking fund (RFSF), which was reflected as restricted cash. The remaining property obligations have been paid from the RFSF.

Per Court Order dated June 14, 2018, the Fund paid a third and final round of property dividends to the claimants from the RFSF in the total amount of approximately \$193,000. These payments were distributed in August 2018 and the RFSF was closed in May 2019.

Basis of Presentation

The financial statements of the Fund have been prepared on the modified cash basis of accounting, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America. Under this method, revenues are recognized when received rather than when earned, and expenses are recognized when paid rather than when the obligations are incurred. The financial statements deviate from the cash basis of accounting in that certain accounts payable are recorded. Settlement fund receivables, estimated claims liabilities, and claim receivables arising from claim overpayments, if any, which are material to the determination of financial position and results of operations, in conformity with accounting principles generally accepted in the United States of America, have not been estimated and are not recorded in the accounts of the Fund. In preparing the financial statements, management evaluated subsequent events through July 8, 2026, the date the financial statements were available to be issued.

Use of Estimates

The preparation of financial statements in conformity with the modified cash basis of accounting requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingencies at the reporting date and revenues and expenses during the reporting period. Actual results could differ from those estimates.

THE PERRINE-DUPONT MEDICAL MONITORING QUALIFIED SETTLEMENT FUND

Notes to Financial Statements

December 31, 2025 and 2024

(Continued)

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Cash and Cash Equivalents

The Fund considers all instruments with an original maturity of three months or less to be cash and cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. These amounts represent actual account balances held by financial institutions at the end of the period, and unlike the balances reported in the financial statements, the account balances do not reflect timing delays inherent in reconciling items such as outstanding checks and deposits in transit. The Fund has never experienced any losses related to these balances.

Income Taxes

The Fund is a qualified settlement fund under Section 468B of the Internal Revenue Code. The Fund was established pursuant to a Court order to resolve certain legal claims, and its assets are segregated from the assets of the defendants. Under Treasury Regulations applicable to qualified settlement funds, the Fund is generally subject to federal income tax on its modified gross income. Amounts transferred to the Fund by, or on behalf of, the defendants are generally excluded from the Fund's income for federal income tax purposes.

The Fund is required to operate on a calendar-year basis and use the accrual method of accounting for federal income tax purposes. At December 31, 2025 and 2024, the Fund had federal net operating loss carryforwards of approximately \$4,351,000 and \$4,288,000, respectively. The net operating loss carryforwards begin to expire in 2034.

The Fund recognizes the effect of income tax positions only when they are more likely than not to be sustained upon examination by taxing authorities. Management has evaluated the Fund's tax positions and determined that the Fund had no material uncertain tax positions requiring recognition or disclosure at December 31, 2025 and 2024. The Fund files income tax returns in the U.S. federal jurisdiction and in West Virginia.

NOTE 2 - COMMITMENTS AND CONTINGENCIES

The Fund was established to administer the medical monitoring program described in Note 1. Under the terms of the settlement, DuPont is required to provide additional funding to the Fund as needed to cover the costs of the medical monitoring program. The Claims Administrator monitors the Fund's available resources and may request additional funding when deemed necessary. The future ability of DuPont to provide additional funding, if required, cannot be determined.